Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: A study of the cancer and leukemia group B

Journal of Clinical Oncology

Volumn 21, Issue 1, 2003, Pages 5-15

  Peterson, Bruce A ^a,b   Petroni, Gina R ^a   Frizzera, Glauco ^a   Barcos, Maurice ^a   Bloomfield, Clara D ^a   Nissen, Nis I ^a   Hurd, David D ^a   Henderson, Edward S ^a   Sartiano, George P ^a   Johnson, Jeffrey L ^a   Holland, James F ^a   Gottlieb, Arlan J ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; BLEOMYCIN; CHOP B PROTOCOL; CHOP-B PROTOCOL; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; VINCRISTINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LYMPHOCYTOMA; MALE; MIDDLE AGED; MIXED CELL LYMPHOMA; MORTALITY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; LYMPHOMA, MIXED-CELL, FOLLICULAR; LYMPHOMA, SMALL CLEAVED-CELL, FOLLICULAR; MALE; MIDDLE AGED; PREDNISONE; REGRESSION ANALYSIS; SURVIVAL RATE; VINCRISTINE;

EID: 18744394609     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/jco.2003.05.128     Document Type: Article

References (73)

1. Rappaport H, Winter WJ, Hicks EB: Follicular lymphoma: A reevaluation of its position in the scheme of malignant lymphoma, based on a survey of 253 cases. Cancer 9:792-821, 1956.
2. Simon R, Durrleman S, Hoppe RT, et al: The non-Hodgkin Lymphoma Pathologic Classification Project: Long term follow-up of 1153 patients with non-Hodgkin lymphomas. Ann Intern Med 109:939-945, 1988.
3. Non-Hodgkin's Lymphoma Pathologic Classification Project: National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas. Summary and description of a working formulation for clinical usage. Cancer 49:2112-2135, 1982.
4. Harris NL, Jaffe ES, Stein H, et al: A revised European-American Classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84:1361-1392, 1994.
5. Harris NL, Jaffe ES, Diebold J, et al: World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meeting-Airlie House. Virginia, November 1997. J Clin Oncol 17:3835-3849, 1999.
6. Jaffe ES, Harris NL, Vardiman HSW: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France; IARC Press, 2001.
7. Portlock CS, Rosenberg SA: No initial therapy for Stage III and IV non-Hodgkin's lymphomas of favorable histologic types. Ann Intern Med 90:10-13, 1979.
8. Horning SJ, Rosenberg SA: The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 311:1471-1475, 1984.
9. Brice P, Bastion Y, Lepage E, et al: Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: A randomized study from the Group D'Etude des Lymphomes Folliculaires. J Clin Oncol 15:1110-1117, 1997.
10. Jones SE, Rosenberg SA, Kaplan HS, et al: Non-Hodgkin's lymphomas. II: Single agent chemotherapy. Cancer 30:31-38, 1972.
11. Fisher RI, Dana BW, LeBlanc M, et al: Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: Results of the Southwest Oncology Group randomized phase III study 8809. J Clin Oncol 18:2010-2016, 2000.
12. Freedman A, Neuberg D, Mauch P, et al: Cyclophosphamide, doxorubicin, vincristine, prednisone dose intensification with granulocyte colonystimulating factor markedly depletes stem cell reserve for autologous bone marrow transplantation. Blood 90:4996-5001, 1997.
13. Young RC, Longo DL, Glatstein E, et al: The treatment of indolent lymphomas. Watchful waiting v aggressive combined modality treatment. Semin Hematol 25:11-26, 1988.
14. Smalley R, Andersen J, Hawkins M, et al: Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma. N Engl J Med 327:1336-1341, 1992.
15. Solal-Celigny P, Lepage E, Brousse N, et al: Recombinant interferon alpha-2-b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. N Engl J Med 329:1608-1614, 1993.
16. Hagenbeek A, Carde P, Meerwaldt JH, et al: Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low grade malignant non-Hodgkin's lymphoma. J Clin Oncol 16:41-47, 1998.
17. Maloney DG, Liles TM, Czerwinski DK, et al: Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84:2457-2466, 1994.
18. Kaminski MS, Zasadny KR, Francis IR, et al: Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 14:1974-1981, 1996.
19. Press OW, Eary JF, Appelbaum FR, et al: Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 346:336-340, 1995.
20. Freedman AS, Gribben JG, Neuberg D, et al: High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 88:2780-2786, 1996.
21. Morel P, Laporte JP, Noel MP, et al: Autologous bone marrow transplantation as consolidation therapy may prolong remission in newly diagnosed high-risk follicular lymphoma: A pilot study of 34 cases. Leukemia 9:576-582, 1995.
22. Fisher RI, Gaynor ER, Dahlberg S, et al: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006, 1993.
23. Coiffier B, Gisselbrecht C, Herbrecht R, et al: LNH-84 regimen: A multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol 7:1018-1026, 1989.
24. Gordon LI, Harrington D, Andersen J, et al: Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med 327:1342-1349, 1992.
25. DeVita VT, Canellos GP, Chabner B, et al: Advanced diffuse histiocytic lymphoma: A potentially curable disease. Lancet 1:248-250, 1975.
26. Schein PS, DeVita VT, Hubbard S, et al: Bleomycin, Adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma. Ann Intern Med 85:417-422, 1976.
27. Schein PS, Chabner BA, Canellos GP, et al: Potential for prolonged disease-free survival following combination chemotherapy of non- Hodgkin's lymphoma. Blood 43:181-189, 1974.
28. Kantarjian HM, McLaughlin P, Fuller LM, et al: Follicular large cell lymphoma: Analysis and prognostic factors in 62 patients. J Clin Oncol 2:811-819, 1984.
29. Wendum D, Sebban C, Gaulard P, et al: Follicular large-cell lymphoma treated with intensive chemotherapy: An analysis of 89 cases included in the LNH87 trial and comparison with the outcome of diffuse large B-cell lymphoma. J Clin Oncol 15:1654-1663, 1997.
30. Bartlett NL, Rizea M, Dorfman RF, et al: Follicular large cell lymphoma: Intermediate or low-grade? J Clin Oncol 12:1349-1357, 1994.
31. Horning SJ, Weiss LM, Nevitt JB, et al: Clinical and pathologic features of follicular large cell (nodular histiocytic lymphoma). Cancer 59:1470-1474, 1987.
32. McKelvey EM, Gottlieb JA, Wilson HE, et al: Hydroxydaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 38:1484-1493, 1976.
33. Durkin WJ, Pugh RP, Solomon J, et al: Treatment of advanced lymphomas with bleomycin (NSC-125066). Oncology 33:140-145, 1976.
34. Crooke ST, Bradner WT. Bleomycin: A review. J Med 7:333-428, 1976.
35. Luce JK, Gamble JF, Wilson HE, et al: Combined cyclophosphamide, vincristine, and prednisone therapy of malignant lymphoma. Cancer 28:306- 317, 1971.
36. Steward WP, Crowther D, McWilliam LJ, et al: Maintenance chlorambucil after CVP in the management of advanced stage, low-grade histologic type non-Hodgkin's lymphoma. Cancer 61:441-447, 1988.
37. Ezdinli EZ, Anderson JR, Melvin F, et al: Moderate versus aggressive chemotherapy of nodular lymphocytic poorly differentiated lymphoma. J Clin Oncol 3:769-775, 1985.
38. Ezdinli EZ, Harrington DP, Kucuk O, et al: The effect of intensive intermittent maintenance therapy in advanced low-grade non-Hodgkin's lymphoma. Cancer 60:156-160, 1987.
39. Carbone PP, Kaplan HS, Musshoff K, et al: Report of the committee on Hodgkin's disease staging. Cancer Res 31:1860-1861, 1971.
40. Warnke RA, Kim H, Fuks Z, et al: The co-existence of nodular and diffuse patterns in nodular non-Hodgkin's lymphomas: Significance and clinicopathologic correlation. Cancer 40:1229-1233, 1977.
41. Lukes RJ, Collin RD: Immunologic characterization of human malignant lymphomas. Cancer 34:1488-1503, 1974.
42. Lennert K, Feller A: Histopathology of Non-Hodgkin's Lymphomas. New York, NY, Springer, 1992.
43. Agresti A: Categorical Data Analysis. New York, NY, John Wiley, 1990.
44. Hosmer T, Lemeshow E: Applied Logistic Regression. New York, NY, John Wiley, 1989.
45. Marubini E, Valsecchi MG: Analysing Survival Data from Clinical Trials and Observational Studies. Chichester, John Wiley, 1995.
46. Rappaport H: Tumors of the hematopoietic system, in Atlas of Tumor Pathology, section 3, fascicle 8. Washington, DC, U.S. Armed Forces Institute of Pathology, 1966.
47. Kennedy BJ, Bloomfield CD, Kiang DT, et al: Combination versus successive single agent chemotherapy in lymphocytic lymphoma. Cancer 41:23-28, 1978.
48. Portlock CS, Rosenberg SA, Glatstein E, et al: Treatment of advanced non-Hodgkin's lymphomas with favorable histologies: Preliminary results of a prospective trial. Blood 47:747-756, 1976.
49. Anderson T, Bender RA, Fisher RI, et al: Combination chemotherapy in non-Hodgkin's lymphoma: Results of long-term follow-up. Cancer Treat Rep 6:1057-1066, 1977.
50. Dana B, Dahlberg S, Bharat N, et al: Long term follow up of patients with low grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. J Clin Oncol 11:644-651, 1993.
51. Glick JH, Barnes JM, Ezdinli EZ, et al: Nodular mixed lymphoma: Results of a randomized trial failing to confirm prolonged disease-free survival with COPP chemotherapy. Blood 58:920-925, 1981.
52. Jones SE, Grozea PN, Metz EN, et al: Superiority of Adriamycincontaining combination chemotherapy in the treatment of diffuse lymphoma. A Southwest Oncology Group Study. Cancer 43:417-425, 1979.
53. Jones SE, Grozea PN, Miller TP, et al: Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone alone or with levamisole or with levamisole plus BCG for malignant lymphoma: A Southwest Oncology Group Study. J Clin Oncol 3:1318-1324, 1985.
54. Lepage E, Sebban C, Gisselbreche C, et al: Treatment of low grade non-Hodgkins lymphomas: Assessment of doxorubicin in a controlled trial. Hematol Oncol 8:31-39, 1990.
55. Lister TA, Cullen MH, Beard MEJ, et al: Comparison of combined and single-agent chemotherapy in non-Hodgkin's lymphomas of favourable histologic type. BMJ 1:533-537, 1978.
56. Hoppe RT, Kushain P, Kaplan HS, Rosenberg SA, Brown BW: The treatment of advanced stage favorable histology non-Hodgkin's lymphoma: A preliminary report of a randomized trial comparing single agent chemotherapy, combination chemotherapy, and whole body irradiation. Blood 58:592-598, 1981.
57. Kalter S, Holmes L, Cabanillas F: Long-term results of treatment of patients with follicular lymphomas. Hematol Oncol 5:127-138, 1987.
58. Rodriguez V, Cabanillas F, Burgess MA, et al: Combination chemotherapy ("CHOP-Bleo") in advanced (non-Hodgkin's) malignant lymphoma. Blood 49:325-333, 1977.
59. Cabanillas F, Smith T, Bodey GP, et al: Nodular malignant lymphomas. Factors affecting complete response rate and survival. Cancer 44:1983- 1989, 1979.
60. Licht JD, Bosserman LD, Andersen JW, et al: Treatment of low-grade and intermediate-grade lymphoma with intensive combination chemotherapy results in long-term, disease-free survival. Cancer 66:632-639, 1990.
61. Gottlieb AJ, Anderson JR, Ginsberg SJ, et al: A randomized comparison of methotrexate dose and the addition of bleomycin to CHOP therapy for diffuse large cell lymphoma and other non-Hodgkin's lymphomas: Cancer and Leukemia Group B Study 7851. Cancer 66:1888-1896, 1990.
62. Gribben JG, Freedman AS, Woo SD, et al: All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood 78:3275-3280, 1991.
63. Longo DL, Young RC, Hubbard SM, et al: Prolonged initial remission in patients with nodular mixed lymphoma. Ann Intern Med 100:651-656, 1984.
64. Gallagher CJ, Gregory WM, Jones AE, et al: Follicular lymphoma: Prognostic factors for response and survival. J Clin Oncol 4:1470-1480, 1986.
65. Mann RB, Berard CW: Criteria for the cytologic subclassification of follicular lymphomas: A proposed alternative method. Hematol Oncol 1:187-192, 1983.
66. Nathwani BN, Metter GE, Miller TP, et al: What should be the morphologic criteria for the subdivision of follicular lymphomas? Blood 68:837-845, 1986.
67. Metter GE, Nathwani BN, Burke JS, et al: Morphological subclassification of follicular lymphoma: Variability of diagnoses among hematopathologists, a collaborative study between the Repository Center and Pathology Panel for Lymphoma Clinical Studies. J Clin Oncol 3:25-38, 1985.
68. Martin AR, Weisenburger DD, Chan WC, et al: Prognostic value of cellular proliferation and histologic grade in follicular lymphoma. Blood 85:3671-3678, 1995.
69. NCI Non-Hodgkin's Classification Project Writing Committee: Classification of non-Hodgkin's lymphomas. Reproducibility of major classification systems. Cancer 55:91-95, 1985.
70. Herrmann R, Barcos M, Stutzman L, et al: The influence of histologic type on the incidence and duration of response in non-Hodgkin's lymphoma. Cancer 49:314-322, 1982.
71. Non-Hodgkin's Lymphoma Classification Project: A clinical evaluation of the International Lymphoma Study Group Classification of non- Hodgkin's Lymphoma. Blood 89:3909-3918, 1997.
72. Pedersen-Bjergard J, Ersbøll J, Sørensen HM, et al: Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents. Ann Intern Med 103:195-200, 1985.
73. Pedersen-Bjergaard J, Ersbøll J, Hansen VL, et al: Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin's lymphoma. N Engl J Med 318:1028-1032, 1988.